Company intelligence / Profile preview

Rapa Therapeutics

Rockville  , Maryland, United Statesrapatherapeutics.com ↗
Ownership
Private
Development stage
Other
01

Overview

Rapa’s lead program RAPA‑501 is an autologous epigenetically reprogrammed TREG/Th2 “hybrid” cell therapy showing safety and biological activity in ALS patients with trends toward slowing pulmonary decline. Their oncology program uses non-genetically engineered rapamycin-resistant Th1/Tc1 cells. Early clinical results include stringent complete remissions in multiple myeloma patients refractory to other treatments. The company’s approach aims to provide less toxic alternatives compared to existing immunotherapies.

Therapeutic areas
OncologyNeurology
Modalities
Autologous T cell therapies (including rapamycin-resistant T cells)Adoptive cell therapyImmunomodulators
Industry
Biotech
02

Drug pipeline

3 assets

RAPA-501

3

2 more assets in the full pipeline.

03

Partnerships

Supported by TEDCO Venture Funds ($1M investment)collaboration with Sean M. Healey & AMG Center for ALS at Mass General Hospitalpartial support from the ALS Association

Beyond the preview

Go deeper on Rapa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapa Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call